Firm moves against asthma among children, unveils antidote
GSK Pharmaceuticals Nigeria has reiterated its commitment to improving asthma control among children. It made the avowal while unveiling a new offering, Flixotide, at the 2019 yearly Paediatrics Association of Nigeria Conference (PANCONF) in Ibadan, Oyo State.
The Medical Director, GSK Nigeria, Dr. Laja Odunuga, said: “The concept is to make controller medication available for children who are less than four years, and the introduction of Flixotide is meant to fill a gap for the children that cannot benefit from other controller medications prescribed for the adult population.”
On the assessment of asthmatic conditions among children in Nigeria, he noted: “I think we are getting better. We are probably not where we want to be but things are getting better in the sense that medications are now readily available.
“We are also trying to tackle the issue of stigmatisation, capacity building for healthcare professionals such as doctors, nurses and pharmacists to ensure that the right things are done at the right time. For the parents, we are advocating that they take up proper health-seeking behaviour. If we put all these parameters together, these are pointers that will reduce the mortality and morbidity associated with this disease.”
The new product, which will be available soon in the country, is a low dose inhaled corticosteroid for prevention of asthma exacerbation in children from age one. The product reduces frequency of asthma symptoms and attacks in patients previously treated with bronchodilators alone or with other prophylactic therapy.
Lauding the pharmaceutical firm on the novelty, the association’s president, Prof. Austin Omoigberale, stated that it is high time relevant bodies and authorities supported initiatives that further guarantee safety and good health for Nigerian children under five years.
“The launch of the product is fantastic. One of the themes of this year’s conference is child health and therapeutic advances. So, we are always happy to partner with pharmaceutical companies like GSK. We have some research work going on, looking at how we can proffer common solutions to childhood diseases,” he said.
No comments yet